Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 11/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | MMP3 | P08254 | 2/20 | 0.44 |
| ▸ | MMP9 | P14780 | 2/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 3/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4059853 | 0.77 | MAPK14 (0.47) | MMP13MMP2MMP3MMP9MMP8 | |
| SCHEMBL6210006 | 0.73 | MMP13 (0.51) | MMP13MMP2MMP3SMN1; SMN2NPSR1 | |
| SCHEMBL1100591 | 0.73 | MMP13 (0.51) | MMP13MMP2MMP3SMN1; SMN2NPSR1 | |
| SCHEMBL1100587 | 0.73 | MMP13 (0.51) | MMP13MMP2MMP3SMN1; SMN2NPSR1 | |
| SCHEMBL1099762 | 0.72 | ALDH1A1 (0.48) | MMP13MMP8SMN1; SMN2NPSR1MMP14 | |
| SCHEMBL1099764 | 0.72 | ALDH1A1 (0.48) | MMP13MMP8SMN1; SMN2NPSR1MMP14 | |
| SCHEMBL4056808 | 0.69 | ADAM17 (0.62) | MMP13MMP2MMP3MMP9MMP8 | |
| SCHEMBL1108471 | 0.67 | ALDH1A1 (0.52) | MMP13MMP2MMP3MMP9MMP8 | |
| SCHEMBL1100647 | 0.66 | HPGD (0.58) | MMP2MMP9MMP8SMN1; SMN2NPSR1 | |
| SCHEMBL7097777 | 0.65 | ALDH1A1 (0.60) | MMP13MMP2MMP9MMP8SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232101-A1 | Novel Compounds | CHAPMAN DAVID (SE) | 2012-09-13 | — | — | US | disclosed |
| US-8183251-B2 | 1-[(4S)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]-N-methyl-N-{[4-(pyrimidin-5-yloxy)phenyl]methyl}methanesulfonamide; matrix metalloproteinase inhibitors; obstructive airways disease is asthma or chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2012-05-22 | — | — | US | disclosed |
| US-8183251-B2 | 1-[(4S)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]-N-methyl-N-{[4-(pyrimidin-5-yloxy)phenyl]methyl}methanesulfonamide; matrix metalloproteinase inhibitors; obstructive airways disease is asthma or chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2012-05-22 | — | — | US | disclosed |
| EP-2097406-B1 | HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS | ASTRAZENECA AB (SE) | 2011-07-20 | — | — | EP | disclosed |
| US-20080221139-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221139-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| WO-2008065393-A1 | HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221139-A1 | Novel Compounds | MMP9, MMP2, MMP1 | MMP13 14/4885MMP2 2/4885MMP3 4/4885 |
| US-20120232101-A1 | Novel Compounds | MMP9, MMP2, MMP1 | MMP13 14/4885MMP2 2/4885MMP3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.